Everest Medicines acquires Greater China rights for LENZ Therapeutics’ VIZZ
LENZ Therapeutics (NASDAQ:LENZ) and Everest Medicines announced an agreement on June 8, 2026, transferring the rights to develop, manufacture, and commercialize LNZ100—marketed in the United States as VIZZ—within Greater China.










